Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 22, 2018
Pharmacy Choice - News - Generic Drugs - February 22, 2018

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 62     Next >>     Go To Page:

2/22/18 - Single-Use Technology for Biopharmaceuticals Market Size Will Escalate Rapidly in the Near Future: Rise in biologics and biosimilars market will ultimately rise the market for Single-use Technology for Biopharmaceuticals.
Albany, NY 02/21/2018 Single-use or disposable products or technology is intended to be used for one time only and then are meant for disposing. These technologies are mainly made from Plastic which are disposed off after use. Single-use technologies have transformed the field of biopharmaceuticals.
2/21/18 - Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR
The product is manufactured here in the United States in the company's recently expanded Brookhaven, New York facility. Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Amneal Pharmaceuticals LLC an
2/21/18 - Biosimilars Market Size Industry Strategy & Forecast Report : Biosimilars Market report has segmented the market into five geographies covering production, consumption, revenue (million USD), and market share and growth rate of Biosimilars market
New York, NY 02/21/2018 Study papers on Biosimilars market and regional forecast. Biosimilars market players are Sandoz International, Hospira, Teva Pharmaceutical, Dr. Reddy's Laboratories, Biocon, Mylan, Amgen, Roche Diagnostics, Merck KGaA. Under the Biologics Price Competition and Innovation Act, an organic item can be resolved to be bios
2/21/18 - Counting the cost of cancer medication [Bizcommunity (South Africa)]
The patient is often the loser in the race between original, clone and generic oncology medication producers... Pharmaceutical companies invest significant resources in researching and developing medications, with their investments protected by patents that let them charge what they need to over a specified period of time to recover their outlay, a
2/21/18 - Diplomat Managing Rising Drug Costs to Support Patients
Diplomat Pharmacy, Inc. plans to combat rising healthcare costs throughout 2018 by advancing generic drugs, biosimilars, and affordable brand medications. Joel Saban, president of Diplomat, said the growing market for high-cost specialty drugs in the U.S. drives up costs for health plans and patients. "With 90 percent of traditional medications
2/21/18 - Glenmark Pharmaceuticals Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea for Ophthalmic Solution Products
Glenmark will seek all market authorizations and commercialize the products in North America. "The agreement for these ophthalmic products is aligned with our strategy to strengthen our focus on complex generic formulations," said Robert Matsuk, President, North America& Global API at Glenmark Pharmaceuticals. It is expected that Glenmark will fil
2/21/18 - Merck Invests Additional ?40 Million to Enhance Manufacturing and Distribution in Asia
-Builds capabilities with two new manufacturing and distribution centres in South Korea and India. "Our investments in the important Asian markets of South Korea, India and China ensure that our customers have ready access to the products needed to develop new therapies and biosimilars that accelerate access to health for people everywhere."
2/21/18 - Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
Momenta Pharmaceuticals today reported its financial results for the fourth quarter and year ended December 31, 2017 and provided a corporate update. With the recent approval and launch of Glatopa 40 mg, the significant advancements we ve made across our novel drug portfolio, and the furthering of both M923, our biosimilar HUMIRA candidate, a
2/21/18 - Mylan Receives Tentative Approval for Combination HIV Treatment DTG FTC TAF under FDA's PEPFAR Program
HERTFORDSHIRE, England and PITTSBURGH- Global pharmaceutical company Mylan N.V. today announced receipt of tentative approval from the U.S. Food and Drug Administration under the U.S. President's Emergency Plan for AIDS Relief for its New Drug Application for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg.
2/21/18 - Perrigo Confirms Patent Challenge For Generic Version Of Finacea Foam, 15%
DUBLIN- Perrigo Company plc today announced that it has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic version of Finacea Foam. Following notification from Perrigo, Bayer AG filed a patent litigation suit asserting patents listed in the Orange Book for Finacea Foam in the United States
2/21/18 - Teva Announces Exclusive Launch of Two Strengths of a Generic Version of Solodyn in the United States
JERUSALEM- Teva Pharmaceutical Industries Ltd., today announced the exclusive launch of two strengths of a generic version of Solodyn1 Extended Release Tablets, 65 and 115 mg, in the U.S.. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in fir
2/21/18 - The American College of Rheumatology recommends biosimilar use in new white paper
By a News Reporter-Staff News Editor at Biotech Week The American College of Rheumatology has published a new white paper, "The Science Behind Biosimilars- Entering a New Era of Biologic Therapy," providing a comprehensive overview of the scientific, clinical, economic and prescribing issues pertaining to biosimilar use, including efficacy, compe
2/20/18 - Chronic Heart Failure Market Top Industry Players, Revenue by 2025
Albany, NY 02/20/2018 The Chronic Heart Failure Market is an advanced market, wherein branded drugs are increasingly being taken over by generic drugs. The CHF market presently has scanty pipeline of brand-name drugs and is heavily laden with generic drugs. Chronic heart failure is a serious condition and is progressive.
2/20/18 - FDA commissioner says hell go after high drug prices [Arab Finance (Egypt)]
Gottlieb also said he wants to speed up the U.S. approval process for generic and biosimilar versions of biologic drugs, which are drugs comprised of living organisms, such as plant or animal cells. He deflected questions about whether the FDA approves drugs of questionable value that have exorbitant prices. The Food and Drug Administration, Gottli
2/20/18 - Impax Announces the Launch of an Authorized Generic Version of Solodyn (Minocycline HCl) Extended-Release Tablets
Impax Laboratories, Inc., a specialty pharmaceutical company, today announced it has launched an authorized generic version of Solodyn extended-release tablets, 65 mg and 115 mg. About Impax Laboratories, Inc. Impax Laboratories, Inc. is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the..
2/20/18 - Intellipharmaceutics Announces Fiscal Year 2017 Results
TORONTO- Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2017. Isa Odidi, CEO of Intellipharmaceutics.' We continue
2/20/18 - Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program
HERTFORDSHIRE, England and PITTSBURGH, Feb. 20, 2018/ PRNewswire/ Global pharmaceutical company Mylan N.V. today announced receipt of tentative approval from the U.S. Food and Drug Administration under the U.S. President's Emergency Plan for AIDS Relief for its New Drug Application for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablet
2/20/18 - Novartis trumpets long-term data for Cosentyx in psoriasis [Syrian Arab News Agency]
Cosentyx has already achieved blockbuster status but is behind Johnson& Johnsons established psoriasis Stelara in terms of sales, with the latter generating more than $4 billion worldwide last year. AbbVies Humira is also often used in psoriasis and will experience cheap biosimilar competition later this year in Europe making the market for psorias
2/20/18 - Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet by Company's Subsidiary Macoven Pharmaceuticals
MORRISTOWN- Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced the launch of an authorized generic version of Treximet in the U.S. by the Company's subsidiary, Macoven Pharmaceuticals, LLC. 'The availability of both a branded and authorized generic version of Treximet demonstrates that Pernix continues to view T
2/20/18 - Perrigo Confirms Patent Challenge For Generic Version Of Finacea Foam, 15%
Perrigo Company plc today announced that it has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic version of Finacea Foam. Following notification from Perrigo, Bayer AG filed a patent litigation suit asserting patents listed in the Orange Book for Finacea Foam in the United States
2/20/18 - SHIRE PLC - 10-K - : Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with the Company's Consolidated Financial Statements contained in ITEM 15: Exhibits and Financial Statement Schedules set forth in this Annual Report on Form 10- K. The Company has grown both organically and through acquisition, completing a series of major transactions that have brought...
2/20/18 - Teva Announces Exclusive Launch of Two Strengths of a Generic Version of Solodyn in the United States
Teva Pharmaceutical Industries Ltd., today announced the exclusive launch of two strengths of a generic version of Solodyn 1 Extended Release Tablets, 65 and 115 mg, in the U.S.. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-f
2/20/18 - The Global Healthy Living Foundation Stands with the FDA and Its Biosimilar Education Efforts
The Global Healthy Living Foundation, and its arthritis community, CreakyJoints, which represents millions of people with arthritis, strongly disagrees with last week s public statement from the Patients for Biologics Safety& Access chiding the FDA for its efforts to educate providers about the critical role biosimilars play in today s health
2/19/18 - Andrew S. Boyer Joins Amneal Pharmaceuticals as Executive Vice President, Commercial Operations
By a News Reporter-Staff News Editor at Pharma Business Week Amneal Pharmaceuticals LLC and Impax Laboratories, Inc., announced that Andrew S. Boyer, 52, has joined Amneal as Executive Vice President, Commercial Operations and is expected to serve in the same capacity for the new combined company following the consummation of the combination with
2/19/18 - Biosimilar Insulin Market Access 2018: Focus on the European and US Markets - ResearchAndMarkets.com
The "Biosimilar Insulin Market Access" report has been added to ResearchAndMarkets.com' s offering. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For...
Articles(s): 1 - 25 of 62     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415